来源：新浪财富汇 作为禾迈股份IPO的保荐机构，中信证券在推动其以A股史上最高发行价上市的过程中发挥了关键作 用，却在后续股价暴跌与公司业绩变脸中面临市场对其职责履行的多重质疑。 一、保荐角色：缔造"天价IPO"与争议性超募 发行定价争议 中信证券作为禾迈股份2021年上市的保荐人，主导其创下557.8元/股的A股最高发行价纪录。询价过程 中出现异常报价区间（52.5元至798元），引发市场对机构串通操纵定价的质疑。原计划募资5亿元，最 终募得55.78亿元，超募率高达1015%，远超公司实际需求（净资产仅5亿元）。 包销弃购股份的短期利益驱动 散户因高估值风险弃购65万股（价值3.63亿元），中信证券全额包销。上市后，中信证券联合机构资金 推动股价在2022年飙升至1338.88元，较发行价暴涨140%，短期套利空间显著。 二、后续股价崩盘：保荐人责任缺位与市场失衡 估值泡沫破裂的推手 利益导向的承销模式 中信证券在禾迈股份基本面支撑不足的情况下，持续发布乐观研报并配合资金炒作。公司2025年业绩骤 变为亏损1.35亿元（同比下滑139%），此前过度包装的成长预期被证伪。股价自高点暴跌83%（复权 价），2 ...

这一年，科创板"1+6"改革举措落地，科创成长层成功设立并迎来首批企业，重启未盈利"硬科 技"企业适用第五套标准上市，并进一步扩大适用范围至人工智能等前沿科技领域，为处于成长期、研 发投入高的科创企业提供专属融资通道。同时，创业板正式启用第三套上市标准，向优质未盈利创新企 业敞开大门，2026年，中国证监会将启动实施深化创业板改革。 数据是最有力的证明。据Wind统计，2025年全年共有116家企业成功登陆A股市场，首发募集资金 合计达1317.71亿元。其中，约九成属于战略性新兴产业，覆盖新一代信息技术、新材料、高端装备制 造等关键领域。从板块情况来看，目前，科创板上市公司已达604家，其中61家在上市时尚未盈利，22 家未盈利企业在上市后实现盈利并"摘U"。 值得一提的是，除IPO入口更加畅通外，并购重组也成为向新质生产力集聚的重要途径。2025年， 沪深上市公司累计披露重大资产重组超200单，标的集中分布于半导体、信息技术、高端装备制造等关 键赛道。业内人士认为，通过并购重组将存量资源整合，进而推动实现产业升级，有助于资源向创新龙 头进一步集中。 当前，资本市场服务科技创新的触角正伸向更前沿的"硬核"领 ...

春江水暖鸭先知。2025年，资本市场投行业务在经历蛰伏后迎来全面回暖，A股募资规模突破万亿元， 同比增长超270%，行业规模与结构同步优化。头部券商优势稳固，市场资源向优质机构集中，竞争格 局日趋清晰。 业内人士认为，近年来，监管层深化注册制改革、坚持"扶优限劣"，引导投行聚焦科技创新，服务实体 经济。2026年开年，投行业务开局稳健，硬科技、并购重组、绿色金融等成为核心增长点，行业正加速 向专业化驱动转型，在政策与市场双重支撑下迈向高质量发展新阶段。 ● 本报记者 赵中昊 谭丁豪 复苏春潮：投行业务规模与结构双提升 经历2024年的调整蓄力，2025年券商投行业务全面复苏，规模与结构实现质的提升。数据显示，2025年 A股股权融资规模突破万亿元，同比增长超270%，行业复苏态势显著。市场集中度进一步向头部聚拢 ——股权承销金额前五的中信证券（600030）、国泰海通（601211）、中金公司（601995）、中银证券 （601696）和中信建投（601066），合计占据超74%的市场份额，形成稳固的第一梯队。 具体来看，行业龙头效应凸显。中信证券以2467.04亿元的总承销金额稳居榜首；2025年完成合并的 ...

春江水暖鸭先知。2025年，资本市场投行业务在经历蛰伏后迎来全面回暖，A股募资规模突破万亿元， 同比增长超270%，行业规模与结构同步优化。头部券商优势稳固，市场资源向优质机构集中，竞争格 局日趋清晰。 业内人士认为，近年来，监管层深化注册制改革、坚持"扶优限劣"，引导投行聚焦科技创新，服务实体 经济。2026年开年，投行业务开局稳健，硬科技、并购重组、绿色金融等成为核心增长点，行业正加速 向专业化驱动转型，在政策与市场双重支撑下迈向高质量发展新阶段。 ● 本报记者 赵中昊 谭丁豪 复苏春潮：投行业务规模与结构双提升 经历2024年的调整蓄力，2025年券商投行业务全面复苏，规模与结构实现质的提升。Wind数据显示， 2025年A股股权融资规模突破万亿元，同比增长超270%，行业复苏态势显著。市场集中度进一步向头 部聚拢——股权承销金额前五的中信证券、国泰海通、中金公司、中银证券和中信建投，合计占据超 74%的市场份额，形成稳固的第一梯队。 具体来看，行业龙头效应凸显。中信证券以2467.04亿元的总承销金额稳居榜首；2025年完成合并的国 泰海通证券表现亮眼，以1475.92亿元跃居第二；中金公司与中银证券 ...

Core Viewpoint - The article discusses the significant decline in the stock prices of ten high-issue-price stocks in the A-share market, with seven of them falling below their issue prices, highlighting the risks associated with high valuations and market sentiment shifts [1][22]. Group 1: Stock Performance - Among the ten stocks, only Stone Technology, Naxin Micro, and BeiGene remain above their issue prices as of mid-February 2026 [6][8]. - The maximum decline from issue prices includes: - CanSino down 69.15% - Wanrun New Energy down 58.54% - Huabao New Energy down 54.93% - Yiqiao Shenzhou down 42.22% - Hemai down 32.82% - Foxit Software down 22.17% - Suocheng Technology down 12.83% [10]. - CanSino experienced a dramatic drop of 93% from its peak price of 797.20 yuan to 63.90 yuan [11][19]. Group 2: Company Backgrounds - Hemai, the highest issue price stock at 557.80 yuan, faced a significant decline after reaching a peak of 1877.43 yuan [12]. - Wanrun New Energy, listed at 299.88 yuan, never reached its issue price after its first day of trading [15]. - Yiqiao Shenzhou, with an issue price of 292.92 yuan, peaked at 353.83 yuan before falling to 73.38 yuan [16]. - CanSino, a COVID-19 vaccine stock, was listed at 209.71 yuan and peaked at 797.20 yuan before its decline [17]. Group 3: Market Conditions and Trends - The high issue prices were driven by market enthusiasm for sectors like hard technology, new energy, and biomedicine during the registration reform period from 2020 to 2023 [5][4]. - The overall market sentiment has shifted, leading to a decline in these stocks as the initial excitement waned [22]. - The article notes that the current new stock market shows a stark contrast, with a recent increase in participation and initial gains, but also warns of accumulating risks [24][26]. Group 4: Investment Implications - The high issue prices and P/E ratios of these stocks are no longer guarantees of company strength, but rather potential warning signs of investment risk [28]. - The article emphasizes that the era of easy profits from new stock subscriptions has ended, requiring more thorough research and disciplined investment strategies [27].

在中国A股市场，借壳上市（Backdoor Listing）是指企业通过将自身资产注入已上市公司（壳公司），获得其控制权并实现间接 上市的过程。相较于IPO（首次公开募股），借壳上市周期短、效率高，但监管严格、操作复杂。以下是A股主板借壳上市的详 细流程及核心要点，结合最新监管规则（如《上市公司重大资产重组管理办法》《上市公司收购管理办法》等）梳理： 目标：锁定符合条件的壳公司，评估交易可行性。 阶段2：尽职调查与方案设计 一、借壳上市的定义与认定标准 根据《上市公司重大资产重组管理办法》（2023年修订），构成借壳上市需同时满足两个条件： 若仅满足"控制权变更"但未触发"资产/业务重大变化"，则不构成借壳，按一般资产重组处理。 二、借壳上市详细流程 阶段1：前期准备与壳公司筛选 目标：全面核查双方风险，制定可行交易方案。 1. 控制权变更：上市公司自控制权发生变更之日起36个月内； 2. 资产/业务重大变化：向收购人及其关联人购买的资产总额、营业收入或净利润占上市公司相关指标的比例达到100%以上 （或导致主营业务根本变化）。 壳公司筛选标准： 市值较小（通常20-50亿元，便于低成本收购）； 股权结构清晰 ...

Group 1 - The core viewpoint of the articles emphasizes the increasing support for technology innovation through capital markets, with a focus on the inclusion of unprofitable companies in the IPO process [1][2][3] - The capital market reforms since 2025 have led to a significant increase in the market capitalization of technology companies, which now account for over a quarter of the A-share market, surpassing traditional sectors like banking and real estate [2][3] - The introduction of more inclusive listing standards, particularly on the Sci-Tech Innovation Board (STAR Market), has facilitated the entry of unprofitable tech companies into the capital market [2][3][4] Group 2 - By the end of 2025, the STAR Market had supported the listing of 600 high-tech and strategic emerging industry companies, with a total market capitalization exceeding 10 trillion yuan and over 1.1 trillion yuan raised through IPOs and refinancing [3][4] - The implementation of the "1+6" reform measures on the STAR Market has enhanced support for technology companies with significant breakthroughs and large R&D investments, even if they are currently unprofitable [3][4] - The growth of private equity and venture capital funds has been crucial in providing the necessary long-term capital for technology innovation, with significant increases in both the number of projects and the amount of capital invested in high-tech enterprises [8][9] Group 3 - The Chinese Securities Regulatory Commission (CSRC) has emphasized the need for a more adaptable and inclusive capital market to better serve the development of new productive forces, focusing on deepening the registration system reform and optimizing listing standards [6][7] - There is a call for differentiated regulatory and delisting mechanisms tailored to the characteristics of technology companies, ensuring that the growth potential of these firms is not hindered by traditional financial metrics [7][10] - The trend of "long money, long investment" is accelerating, with significant contributions from pension funds and insurance capital to public and private equity funds, indicating a growing commitment to supporting innovative enterprises [10]

Group 1 - The core viewpoint is that the development logic of listed companies has shifted from scale expansion and short-term arbitrage to value creation and long-term win-win scenarios, with a focus on technology-driven new productive forces [1] - Capital is increasingly concentrating on high-quality innovative enterprises, with shareholder returns deeply linked to corporate value [1] - Companies are accelerating their global industrial chain layout as part of this new development logic [1] Group 2 - The China Securities Regulatory Commission (CSRC) emphasizes the need to promote the growth of listed companies' value and governance, focusing on building an ecosystem that matches high-quality development [2] - Key aspects of institutional construction include creating a system that supports superior companies while limiting weaker ones, promoting high-level circulation of capital, technology, and industry [2] - The issuance system should shift from "approvability" to "investability" to enhance the alignment between listed companies and new productive forces [2] Group 3 - The focus should be on three areas for high-quality development: deepening the registration system reform, constructing a "long money long investment" ecosystem, and solidifying corporate governance and return foundations [3] - The issuance side should emphasize information quality and sustainable operational capabilities to allow truly competitive companies to enter the market [3] - Long-term capital should be cultivated to stabilize market pricing and encourage companies to prioritize shareholder returns through mechanisms like dividends and buybacks [3]

Core Viewpoint - The recent organizational restructuring announcement by Zhongtai Securities highlights a trend in the securities industry towards breaking down internal barriers and optimizing resource allocation to enhance professional capabilities and overcome development bottlenecks [1][2]. Group 1: Organizational Restructuring - The restructuring at Zhongtai Securities includes the establishment of underwriting, proprietary trading, and research consulting subsidiaries, while dissolving existing committees to streamline operations [2]. - The trend of organizational restructuring is not limited to Zhongtai Securities; leading brokerages are integrating resources to achieve scale and synergy, while smaller firms are focusing on specialized and differentiated advantages [2][3]. - For instance, Guotai Junan initiated a restructuring in April 2022, creating multiple operational committees to enhance customer service and overall strength through deep resource integration [2]. Group 2: Strategic Transformation - The adjustments in organizational structure are part of a broader strategic transformation, aligning with capital market reforms and the needs of the real economy [5]. - The dynamic changes in market demand, particularly due to the registration system reform, necessitate continuous optimization of brokerage structures to enhance service capabilities and meet regulatory requirements [5]. - Southwest Securities exemplifies this trend by reinforcing its focus on the Chongqing region and establishing a sustainable development model through dedicated service efforts [5]. Group 3: Future Directions - Future organizational adjustments in the brokerage sector are expected to move towards a "platform + vertical" integration model, leveraging technology for data and risk management while establishing specialized subsidiaries [6][7]. - Smaller brokerages should focus on regional or specific client segments, adopting a lightweight and agile organizational structure to avoid direct competition with larger firms [7]. - Larger brokerages are encouraged to enhance global asset allocation and comprehensive financial service capabilities through subsidiary spin-offs and international structural development [7].

Core Viewpoint - The case of individual Yuhan manipulating the stock price of "Doctor Glasses" (300622.SZ) has concluded, resulting in severe legal penalties, highlighting the regulatory authority's commitment to combating long-term and covert market manipulation [2][5]. Group 1: Case Overview - Yuhan's manipulation activities spanned over five years, from June 25, 2019, to August 16, 2024, covering 1,252 trading days, making it one of the longest and most complex cases of individual market manipulation [2][3]. - The China Securities Regulatory Commission (CSRC) issued an administrative penalty decision, confiscating Yuhan's illegal gains of 510.89 million yuan and imposing an equal fine, totaling 1.02178 billion yuan [2][3]. Group 2: Manipulation Techniques - Yuhan utilized 67 securities accounts, including 12 under his name, to conduct continuous trading and wash trading, achieving illegal profits of 510.89 million yuan [3][4]. - The manipulation process was divided into three phases: accumulation and initial price increase (June 2019 to May 2021), high-level wash trading and price maintenance (May 2021 to January 2024), and gradual liquidation (January to August 2024) [3][4]. Group 3: Market Impact - During the manipulation, Yuhan's accounts held over 10% of the circulating shares for more than 1,000 trading days, with 150 days exceeding 20%, providing a significant advantage for price manipulation [4]. - The stock price of "Doctor Glasses" rose from 13.72 yuan per share to 37.81 yuan per share, a total increase of 175.58%, while the Shenzhen Composite Index fell by 9.36%, indicating a significant deviation of 184.94 percentage points [4]. Group 4: Regulatory Response - The CSRC rejected Yuhan's defense claims of lacking intent and minimal impact on stock prices, affirming the direct causal relationship between his actions and the abnormal price fluctuations [5]. - The successful prosecution of Yuhan serves as a warning to investors and underscores the regulatory body's determination to maintain fairness and justice in the capital market, especially in the context of ongoing registration system reforms [5].